Anixa Biosciences, Inc. (ANIX) Balance Sheet

The consistent decline in total assets over the last ten quarters underscores the company's reliance on existing capital to sustain its R&D-heavy business model. This downward trajectory suggests that without a successful clinical milestone or external financing, the firm's ability to support its current pipeline will continue to diminish.

While the current ratio remains elevated due to low current liabilities, this metric is misleading for a pre-revenue biotech where cash is the only meaningful liquid asset. Investors should monitor the cash-to-burn ratio closely, as the current balance appears insufficient to support long-term clinical trial continuity.

The erosion of equity highlights the high cost of maintaining an asset-light, partnership-driven research model. Given the lack of internal cash generation, further equity issuance appears likely, which may continue to dilute existing shareholders as the company seeks to bridge its funding gap.